{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000183","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.181594+00:00","generated_at":"2026-05-30T02:59:43.453066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M","bullets":["Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).","Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).","FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.","Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.","12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000183","json":"https://secwatch.observer/filing/0001867096-24-000183.json","markdown":"https://secwatch.observer/filing/0001867096-24-000183.md","text":"https://secwatch.observer/filing/0001867096-24-000183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/0001867096-24-000183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/xers-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:59:43.453066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}